Cellectis S.A. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K, filed on November 5, 2020, by Cellectis S.A., a foreign private issuer based in Paris, France, incorporates by reference the company's interim report for the nine-month period ended September 30, 2020. The filing serves to update U.S. investors on material events and financial status as required under Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934.
Key Financial Metrics
The provided text is a cover sheet and does not contain specific financial data. Consequently, values for revenue, profit, cash flow, margins, debt, and liquidity are not available in this excerpt. The detailed financial metrics are contained within Exhibit 99.1 (the interim report), which is referenced but not included in the input text.
Material Changes
No material changes versus the prior comparable period are described in the provided text. The document solely establishes the filing of the interim report for the nine months ended September 30, 2020.
Guidance, Outlook, and Risks
The text does not provide management commentary, future guidance, specific risks, contingencies, or unusual items. These disclosures are expected to be found within the full interim report attached as Exhibit 99.1.
Investor Verification Checklist
- Verify the full content of Exhibit 99.1 (Interim Report for the nine months ended September 30, 2020) for actual financial figures.
- Confirm the incorporation by reference into registration statements Form F-3 (No. 333-238881) and Form S-8 (Nos. 333-204205, 333-214884, 333-222482, and 333-227717).
- Review the interim report for any updates on clinical trials or strategic partnerships not detailed in this cover sheet.